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Janelle Koppenhaver, MA, Sabine Braat, MS, Qi Zhu, PhD, Mary Mackle, PhD,
Kiki Chang, MD, Maju Mathews, MDObjective: To evaluate asenapine versus placebo in 403
patients aged 10 to 17 years with bipolar I disorder
currently in manic or mixed episodes.
Method: In this double-blind, placebo-controlled, interna-
tional trial, patients were randomized 1:1:1:1 to placebo,
asenapine 2.5, 5, or 10 mg b.i.d. (twice daily). Primary ef-
ﬁcacy measure was change from baseline in Young-Mania
Rating Scale (YMRS) total score at day 21. Analyses of pa-
tientswith/without attention-deﬁcit/hyperactivity disorder
(ADHD) and with/without stimulant use were performed.
Results: The mean difference in asenapine versus placebo
in YMRS was –3.2 (p ¼ .0008), –5.3 (p < .001), and –6.2
(p < .001) for asenapine 2.5, 5, and 10 mg b.i.d., respec-
tively. Treatment-emergent adverse events with an inci-
dence 5% and at least twice placebo were somnolence,
sedation, hypoesthesia oral, paresthesia oral, and
increased appetite. The asenapine groups had a higher
incidence of 7% weight gain (range, 8.0%–12.0%) versus
placebo (1.1%; p < .05). The mean change from baseline in
fasting insulin was larger for patients treated with ase-
napine than those with placebo (asenapine 2.5 mg b.i.d.:Supplemental material cited in this article is available online.
www.jaacap.org73.375 pmol/L; asenapine 5 mg b.i.d.: 114.042 pmol/L;
asenapine 10 mg b.i.d.: 59.846 pmol/L; placebo: 3.690
pmol/L). The mean changes from baseline for lipid pa-
rameters and glucose were also larger in asenapine groups
than in the placebo group. No safety differences were
observed with respect to ADHD and stimulant use.
Conclusion: All asenapine doses versus placebo were
superior based on change in YMRS at day 21. Asenapine
was generally well tolerated in patients aged 10 to 17
years with bipolar I disorder in manic or mixed states.
Increases in weight and fasting insulin were associated
with asenapine.
Clinical trial registration information—Efﬁcacy and
Safety of Asenapine Treatment for Pediatric Bipolar Dis-
order; http://clinicaltrials.gov; NCT01244815.
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J Am Acad Child Adolesc Psychiatry 2015;54(12):1032–1041.ipolar I disorder is a common and often debilitating
psychiatric disorder, the onset of which often occursB during childhood and adolescence. Post et al.1 found
that pediatric age (<18 years) at onset is common (50% of
adults) and is associated with a more severe course of illness.
Other studies have shown individuals with early-onset
bipolar I disorder to have a more chronic, severe, and recur-
rent course compared to those with adult-onset illness.2-4
Moreover, Post et al. demonstrated that delay to ﬁrst treat-
ment was inversely correlated with age of onset and directly
associated with more time depressed, greater depression
severity, more episodes, and more days of cycling.1 There-
fore, earlier recognition, diagnosis, and treatment of bipolar
I disorder is warranted. Comorbid attention-deﬁcit/
hyperactivity disorder (ADHD) and concomitant stimulant
therapy are also common in this age group.5
Several atypical antipsychotics (risperidone, aripiprazole,
quetiapine, and olanzapine) have demonstrated efﬁcacy in
treating children and adolescents with acute manic or mixedepisodes.6-9 In adults, the frequency at which patients are
switched from initial therapy to a second or third therapy is
high.10 Adolescents with bipolar I disorder often have mul-
tiple trials of different antipsychotics,11 possibly as a result of
efﬁcacy and/or tolerability issues in this heterogeneous
population. Thus, additional data and pharmacologic
options are needed.12
Asenapine is a novel sublingual, second-generation,
atypical antipsychotic. The pharmacological proﬁle of ase-
napine displays antagonism for a combination of serotonin,
dopamine, noradrenaline, and histamine receptors.13-16 Its
unique receptor signature may explain the observed ability
of asenapine to improve symptoms associated with bipolar I
disorder.14 In the United States, asenapine has been
approved in adults for use as monotherapy or adjunctive
therapy with lithium or valproate for manic or mixed epi-
sodes associated with bipolar I disorder and as monotherapy
in pediatric patients aged 10 to 17 years.17 Based on a
comparison of adult and pediatric trials, the pharmacoki-
netics of asenapine are similar between pediatric patients
aged 10 to 17 years and adults. In the pediatric population,
asenapine is rapidly absorbed with maximum plasma con-
centrations achieved within 1.5 hours (range, 0.5–3 hours),
with an initial rapid decline in plasma concentrationsJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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ASENAPINE IN PEDIATRIC BP-Ifollowed by a slower elimination phase.18 Asenapine
exposure increases in a dose-proportional manner over the
range of 1 to 10 mg. The systemic pharmacokinetics
(i.e., clearance and volume of distribution) are linear with
respect to time and dose. Steady state is achieved within 6
to 8 days of twice daily (b.i.d.) dosing, consistent with a
terminal elimination half-life of approximately 20 hours
(range, 16–25 hours).
The current study was conducted as part of a post-
marketing requirement to evaluate the efﬁcacy and safety
of asenapine versus placebo (PBO) in pediatric patients
with manic or mixed episodes associated with bipolar I
disorder.METHOD
Participants and Study Design
This was a 3-week, randomized, double-blind, PBO-controlled,
parallel-group trial of asenapine in patients aged 10 to 17 years with
an acute manic or mixed episode associated with bipolar I disorder
(NCT01244815) (Figure 1A). The study was conducted from July 25,
2011 to September 17, 2013, at 86 centers: 76 in the United States and
10 in Russia. A primary diagnosis of bipolar I disorder according
to the DSM-IV-TR with current manic (296.4x) or mixed (296.6x)
episodes with or without psychotic features was required and
conﬁrmed by a structured clinical interview; this consisted of a
medical and psychiatric history, DSM-IV-TR checklist, and the
Kiddie–Schedule for Schizophrenia and Affective Disorders—Pre-
sent and Lifetime Version (K-SADS-PL) at screening. Additional
inclusion criteria included a total Young Mania Rating Scale (YMRS)
score of 20; an overall severity of bipolar mania and bipolar
depression 4 on the Clinical Global Impression scale for use in
Bipolar Illness (CGI-BP overall); and a guardian living with the child
who was able to ensure adherence with treatment, outpatient visits,
and study protocol. Patients were excluded if they had a pervasive
development disorder; schizophrenia; schizoaffective disorder;
posttraumatic stress disorder; obsessive-compulsive disorder; psy-
chosis due to a medical condition or prohibited concomitant medi-
cation; or an uncontrolled, unstable, clinically signiﬁcant medical
condition.
Patients were randomized 1:1:1:1 to PBO or asenapine: 2.5 mg
b.i.d. from day 1; 5 mg b.i.d. administered as 2.5 mg b.i.d. for 3 days,
then 5 mg b.i.d. thereafter; and 10 mg b.i.d. administered as 2.5 mg
b.i.d. for 3 days, then 5 mg b.i.d. for 3 days, then 10 mg b.i.d.
thereafter. Asenapine was administered as a fast-dissolving, black-
cherry–ﬂavored sublingual tablet; PBO was administered by the
same method. The trial included a 2- to 14-day screening/tapering
period for precluded concomitant medications (antipsychotics,
depot neuroleptics, benzodiazepines [except for lorazepam, up to 4
mg daily, or otherwise the equivalent dose of short-acting benzo-
diazepines that were clinically indicated], antidepressants, mood
stabilizers, miscellaneous psychotropics, and herbal drugs/dietary
supplements for depression, anxiety, or insomnia), a 21-day treat-
ment period, and a 30-day follow-up period if the patient did not
enter the open-label, ﬂexible asenapine-dose, long-term extension
trial. The following agents were permitted during the trial: chronic
use medication if the patient’s condition was stable and the dose
stabilized before the ﬁrst dose of study medication, for example,
hormonal birth control; common over-the-counter medications (i.e.,
nutritional supplements, pain relievers, antacids); short-acting ben-
zodiazepines (e.g., lorazepam and equivalents) as needed for the
treatment of agitation, irritability, restlessness, insomnia, and hos-
tility; use of psychostimulants and other ADHD medicationsJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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as long as the same dose was maintained for at least 30 days before
randomization and was not altered during the study (atomoxetine,
methylphenidate, amphetamine, guanfacine); medications to treat
extrapyramidal symptoms (EPS; e.g., anticholinergics, short-acting
benzodiazepines). For countries in which no short-acting benzodi-
azepines are approved by regulatory authorities, diazepam up to
40 mg daily was permitted.
After a 7- to 14-day screening/tapering period, study visits
occurred on days 1, 4, 7, 14, and 21. The total target sample size
was 400 patients. With this sample size, a difference between at
least 1 asenapine dose and PBO of 4.7 points at day 21 in the
change from baseline YMRS total score (i.e., primary analysis)
would be detected with at least 85% power, assuming a standard
deviation of approximately 10 at day 21, a drop-out rate after
3 weeks of 30% in each asenapine group, and 40% in the PBO
group, and a 2-sided signiﬁcance level of .05 with multiplicity
correction according to the procedure of Hochberg.19 Assumptions
were based on results of 2 trials of asenapine in adults with bipolar
mania as well as publications of bipolar mania in children and
adolescents on other antipsychotics.20-22 This trial was conducted
in accordance with Good Clinical Practice standards and applicable
country and/or local statutes regarding ethical committee review,
informed consent, and the protection of human participants in
biomedical research. Before trial initiation, proposed raters from
each site participated in instrument standardization rater training
(K-SAD-PL and YMRS) to ensure that they were qualiﬁed. Raters
were also certiﬁed to administer the YMRS by a rater training
group.
Efﬁcacy
The primary objective was to test the clinical and statistical superi-
ority of at least 1 dose of asenapine compared to PBO, as measured
by change from baseline in YMRS total score at day 21. The YMRS is
an 11-item clinician-rated scale to assess the severity and symptoms
of manic episodes that can range from 0 (all symptoms absent) to 60
(all symptoms extreme).23-25 A decrease in YMRS from baseline is
indicative of improved symptoms. The key secondary analysis was
to test the superiority of at least 1 dose of asenapine compared to
PBO, measured by the change from baseline in severity of bipolar
illness on overall score of the CGI-BP scale at day 21. The CGI-BP
scale is a 1-item clinician-rated scale with a possible score of
1 to 7, where higher scores indicate greater severity.26
Other secondary measures included a decrease of at least 50%
from baseline in YMRS total score (YMRS responder rate) at day 21
of asenapine versus PBO, the change in Children’s Global Assess-
ment Scale (CGAS) from baseline to day 21, and the change in
Children’s Depression Rating Scale, Revised (CDRS-R) total score
from baseline to days 7, 14, and 21. The CGAS is a 100-point scale
that measures psychological, social, and school functioning in ado-
lescents aged 6 to 17 years27; higher scores are associated with better
functioning. The CDRS-R is a 17-item scale to assess the severity and
presence of depressive symptoms in children and adolescents28-30;
higher scores indicate higher severity of symptoms. Fourteen items
are rated from 1 to 7, and 3 items are rated from 1 to 5, with total
scores ranging from 17 to 113. Based on the CDRS-R, a patient was
categorized with emergent depression if the endpoint total score
was 40, provided that the baseline score was <40. The Columbia–
Suicide Severity Rating Scale (C-SSRS) was used to assess suicidal
ideation/behavior.31
Prespeciﬁed subgroup analyses in YMRS total score were con-
ducted in patients based on the presence/absence of comorbid
ADHD, concomitant stimulant use, gender, and age of bipolar I
disorder onset.www.jaacap.org 1033
FIGURE 1 Study design and patient disposition. (A) aThe screening/tapering period took typically between 2 and 14 days, but
could be shorter or longer as clinically warranted. bEach patient randomly assigned to treatment took the first dose of medication at
the trial site, under supervision of trial staff. Randomization and administration of the first dose must have occurred on the same day.
cPatients randomly assigned to asenapine 5 mg b.i.d. (twice daily) received 2.5 mg b.i.d. until their day 4 visit. At the day 4 visit, the
dose of asenapine was increased to 5 mg b.i.d. for the rest of the treatment period. dPatients randomly assigned to asenapine 10 mg
b.i.d. received 2.5 mg b.i.d. until their day 4 visit and 5 mg b.i.d. until their day 7 visit. At the day 7 visit, the dose of asenapine was
increased to 10 mg b.i.d. for the rest of the treatment period. (B) APaT ¼All patients as treated. aOf which 0 were due to the disease
under study.
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FINDLING et al.Safety
Key treatment-emergent adverse events (TEAEs) included akathisia;
dizziness; insomnia; somnolence, hypersomnia, and sedation com-
bined; oral hypoesthesia and dysgeusia combined; EPS; and 7%
weight gain from baseline. AEs were considered treatment emergent
if they were newly reported after baseline or worsened in severity
since baseline. All TEAEs were summarized descriptively by the
Medical Dictionary for Regulatory Activities (MedDRA) system
organ class (SOC) and preferred term (PT) or a Standardized1034 www.jaacap.orgMedDRA Query (SMQ). EPS was deﬁned using SMQ narrow, which
included akathisia, dyskinesia, dystonia, and Parkinson-like events.
Narrow SMQs are intended to enhance speciﬁcity because they are
more likely to represent the condition of interest.32 The EPS Rating
Scale was used to measure EPS; the instrument consists of 4 multi-
item scales with item ratings of 0 to 3 or 0 to 6 for evaluation of
Parkinsonism; akathisia, dystonia, and dyskinesia symptoms; and
individual CGI-Severity scales for evaluation of terms in the narrow
SMQ (each rated from 0 to 8).33 Ratings were made through aJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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AEs were reported and coded using the current version of MedDRA
(MedDRA 16.0). Key laboratory variables were examined as
the change from baseline to endpoint. These included fasting
glucose, triglycerides, cholesterol, and insulin, prolactin, and
hemoglobin A1c. In addition to hematology-, chemistry-, and
endocrinology-related AEs, AEs related to orthostatic hypotension
(PTs: confusional state, dizziness, orthostatic hypotension, postural
orthostatic tachycardia syndrome, vertigo, and presyncope),
sleep disturbances, potential drug abuse, SMQ suicide/self-injury
(broad), SMQ Torsade de Pointes/QT prolongation (broad), SMQ
hyperglycemia/new-onset diabetes mellitus (broad), SMQ liver-
related investigations, signs, and symptoms (broad), together with
SMQ biliary system-related investigations (broad), were evaluated.Statistical Analysis
For allocation of patients, a computer-generated randomization list
was used, which was created by the sponsor using SAS statistical
software (SAS Institute, Cary, NC) and stratiﬁed by site with a 1:1:1:1
allocation using a block size of 4. Allocation of patients and medi-
cation was performed using an interactive voice response system by
an independent third-party vendor. All patients and study staff
remained blinded to treatment until after the last patient visit; active
treatment and placebo were identical in appearance to maintain the
blind. The full analysis set (FAS) data were used to analyze efﬁcacy,
and included all randomized patients who received at least 1 dose of
study medication and had both baseline and at least 1 postbaseline
in-treatment YMRS total score. The primary efﬁcacy endpoint was
analyzed using a mixed model for repeated measures (MMRM)
approach, including factors of site, treatment, visit, treatment-by-visit
interaction, baseline YMRS total score, and baseline YMRS total score
by visit interaction. The CGI-BP and CDRS-R were analyzed using
the MMRM method described for the primary efﬁcacy variable,
substituting the relevant baseline measurement as the covariate. A
logistic regression model was used to analyze YMRS 50% re-
sponders, and CGAS was evaluated using analysis of covariance.
The Hochberg testing procedure was applied for the YMRS and
CGI-BP measures on day 21 using a 2-sided a level of 0.05 to correct
for multiplicity of the 3 asenapine-to-PBO comparisons.19 Associated
95% CIs on day 21 for these two measures were not adjusted for
multiplicity. To ascertain whether the treatment effect on day 21 was
consistent across various prespeciﬁed subgroups for the YMRS total
score, an interaction test was performed.
Safety data were analyzed using the all-patients-as-treated
group, which included all patients who were randomly assigned
and received 1 dose of study medication. Statistical testing using
p values was performed for key AEs, laboratory variables of interest,
and weight. Every patient was counted a single time for each
applicable AE and dose category. Change in weight was calculated
for patients with a baseline and at least 1 postbaseline value. Sta-
tistical comparisons were made between PBO and asenapine at
the 2-sided signiﬁcance level of p < .05 using Mietinnen and
Nurminen34 for proportions and an analysis of covariance model for
continuous data. No correction for multiplicity was used. Predeﬁned
limits of change were used to assess laboratory values, vital signs,
and anthropometric parameters.RESULTS
Patient Disposition and Demographics
Of 537 patients screened, 404 were randomized and 403
were treated (all-patients-as-treated) (Figure 1B). Of these,
395 were included in the FAS, and the overallJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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Groups were similar with respect to demographic variables
such as gender, race/ethnicity, and age (Table 1). A small
percentage of individuals in each treatment group reported a
current history of psychotic features (5.0%, PBO; 12.5%,
asenapine 2.5 mg b.i.d.; 5.1%, asenapine 5.0 mg b.i.d.; and
8.1%, asenapine 10.0 mg b.i.d.). ADHD was the most com-
mon comorbid Axis I disorder among patients, which was
present in 216 patients (54.6%). A slightly lower prevalence
of ADHDwas reported with asenapine 5 mg b.i.d. compared
with the other 3 groups: 62 (59.6%), 45 (45.5%), 61 (61.6%),
and 52 (51.5%) for asenapine 2.5 mg, 5 mg, 10 mg b.i.d.,
and PBO, respectively. Overall, 96 (24%) patients had
concomitant stimulant use.
Efﬁcacy
Each dose of asenapine demonstrated statistical superiority
to PBO in improving YMRS total score from baseline to day
21, with signiﬁcant differences observed from day 4 onward
(Figures 2A and 3A). Similar efﬁcacy was observed in US and
Russian sites, which enrolled 378 and 26 patients, respec-
tively. YMRS symptom scores are provided in Table S1,
available online. For YMRS and CGI-BP, the 95% CI is
unadjusted, and the p value was adjusted at day 21; all other
p values are unadjusted as described in the statistical section.
Furthermore, all 3 doses of asenapine had signiﬁcantly
higher 50% YMRS responder rates (range, 42%–54%)
compared with PBO (28%) at endpoint (Table S2A, available
online). Likewise, all 3 asenapine groups demonstrated sta-
tistically signiﬁcant superiority to PBO in improving the
CGI-BP severity score from baseline to day 21 (Table S2B,
available online); differences were statistically signiﬁcant
from day 7 (Figure 2B). Similarly, all 3 doses of asenapine
were signiﬁcantly superior to PBO in improving the CGAS
score at day 21 (Table S2B, available online). Moreover, ase-
napine 5 mg b.i.d. was signiﬁcantly superior to PBO in
improving CDRS-R total score from day 7 until day 21. Dif-
ferences in CDRS-R total score for asenapine 2.5 mg and
asenapine10mgb.i.d.were signiﬁcantonlyonday7.However,
thepercentages ofCDRS-Remergentdepressionatday21were
comparable among all 3 asenapine doses (2.5 mg b.i.d.: 1.0%, 5
mg b.i.d.: 2.1%, 10 mg b.i.d.: 2.1%) and PBO (3.1%).
Subgroup analyses revealed no signiﬁcant difference in
asenapine versus PBO in change in YMRS total score from
baseline to day 21 between patients with and without
ADHD (Figure 3B) and between patients with and without
concomitant stimulant use (Figure 3C). No signiﬁcant dif-
ference was observed between patients with onset of bipolar
I disorder 11 years and those with onset >11 years
(Figure S1A, available online) or with respect to gender
(Figure S1B, available online).
Safety
There were no deaths during the study. Serious AEs were
3%, 0%, 2%, and 2% for PBO, asenapine 2.5 mg b.i.d., 5 mg
b.i.d., and 10 mg b.i.d., respectively (Table 2). All serious
AEs were in the psychiatric disorders SOC, and most were
considered worsening of the patient’s bipolar I disorder. Thewww.jaacap.org 1035
TABLE 1 Patient Characteristics
Characteristic
Placebo
n ¼ 101
Asenapine
Total
n ¼ 403
2.5 mg
n ¼ 104
5 mg
n ¼ 99
10 mg
n ¼ 99
Female, n (%) 63 (62.4) 52 (50.0) 56 (56.6) 41 (41.4) 212 (52.6)
Race/ethnicity, n (%)
White 68 (67.3) 75 (72.1) 67 (67.7) 65 (65.7) 275 (68.2)
African American/black 23 (22.8) 21 (20.2) 26 (26.3) 27 (27.3) 97 (24.1)
Asian 0 1 (1.0) 0 2 (2.0) 3 (0.7)
Multiracial 9 (8.9) 7 (6.7) 3 (3.0) 5 (5.1) 24 (6.0)
Age, y
Mean (SD) 13.7 (2.0) 13.7 (2.1) 13.8 (2.0) 13.9 (2.1) 13.8 (2.0)
Range 10e17 10e17 10e17 10e17 10e17
Age of onset of bipolar I disorder, y
Mean (SD) 11.5 (2.8) 10.7 (2.7) 11.3 (2.8) 10.6 (3.1) 11.0 (2.9)
 11 years, n (%) 47 (46.5) 65 (62.5) 51 (51.5) 61 (61.6) 224 (55.6)
Current diagnosis, n (%)
Manic (DSM-IV 296.4x) 44 (43.6) 40 (38.5) 43 (43.4) 44 (44.4) 171 (42.4)
Mixed (DSM-IV 296.6x) 57 (56.4) 64 (61.5) 56 (56.6) 55 (55.6) 232 (57.6)
Other Axis I or Axis II, yes, n (%) 65 (64.4) 66 (63.5) 59 (59.6) 66 (66.7) 256 (63.5)
Comorbid ADHD, yes, n (%) 52 (51.5) 62 (59.6) 45 (45.5) 61 (61.6) 220 (54.6)
Concomitant stimulant use, yes, n (%) 20 (19.8) 29 (27.9) 22 (22.2) 25 (25.3) 96 (23.8)
YMRSa, mean (SD) 29.9 (5.5) 29.5 (5.7) 30.3 (5.9) 30.2 (5.6) 30.0 (5.7)
CGI-BP-Sa (overall), mean (SD) 4.3 (0.5) 4.5 (0.6) 4.4 (0.6) 4.4 (0.6) 4.4 (0.6)
Baseline antipsychotic and mood stabilizers
that were discontinued before baseline, n (%)
Antipsychotics 46 (45.5) 44 (42.3) 49 (49.5) 41 (41.4) 180 (44.7)
Mood stabilizers 12 (11.9) 22 (21.2) 26 (26.3) 26 (26.3) 86 (21.3)
Note: CGI-BP-S (overall) ¼ Clinical Global Impression scale for use in Bipolar illness Severity, including mania and depression; YMRS ¼ Young-Mania Rating Scale.
aValues are based on the full analysis set. All other characteristics are derived from all patients as the treated set.
FINDLING et al.overall rate of discontinuation was generally low and similar
among treatment groups (Figure 1b; Table S3, available on-
line). The most common reason for discontinuation in the
PBO group was noncompliance with the protocol. Most
asenapine discontinuations were attributed to AEs, although
there was no correlation with the dose of asenapine
(asenapine 2.5 mg 6.7%, 5 mg 5.1%, 10 mg 5.1%). Among
AEs leading to discontinuation (Table S3, available online),
psychiatric disorders were the most common SOC leading to
discontinuation, which were reported by 4 (4.0%), 3 (2.9%),
3 (3.0%), and 0 (0.0%) patients in the PBO, asenapine 2.5 mg,
5 mg, and 10 mg b.i.d. groups, respectively. AEs reported
under the SOC nervous system disorders were the next most
frequently reported AEs among patients who discontinued
in the asenapine groups (none were reported for PBO).
Within this SOC, somnolence was most common, reported
by 5 asenapine-treated patients who discontinued treatment
(an additional asenapine-treated patient discontinued
because of sedation).
A signiﬁcantly higher incidence of the combination of
somnolence, sedation, and hypersomnia occurred in the ase-
napine treatment groups versus PBO: 2.5 mg (47.1% versus
11.9%), 5 mg (52.5% versus 11.9%), and 10 mg b.i.d. (48.55%
versus 11.9%) (Table 2). There was also a signiﬁcantly higher
incidence of the combination of oral hypoesthesia with1036 www.jaacap.orgdysgeusia in each of the 3 asenapine groups compared with
PBO. There were no signiﬁcant differences among the 3 asena-
pine dose groups and PBOwith respect to akathisia, insomnia,
and EPS (as identiﬁed by the MedDRA SMQ narrow). TEAEs
with an incidence of5%and at least twice that of PBO for each
of the asenapine groups were somnolence, sedation, hypo-
esthesia oral, paresthesia oral, and increased appetite.
A signiﬁcantly higher incidence of 7% weight gain from
baseline to endpoint was observed for asenapine 2.5 mg,
asenapine 5 mg, and asenapine 10 mg b.i.d. versus PBO
(12.0%, 8.9%, 8.0%, respectively, versus 1.1%) (Table 2). The
mean change in the body mass index (BMI) from baseline to
endpoint was also signiﬁcantly greater in the asenapine dose
groups compared to PBO (mean BMI [SD]): 0.06 kg/m2
(0.72), 0.60 kg/m2 (0.79), 0.57 kg/m2 (0.89), and 0.49 kg/m2
(0.81), PBO; asenapine, 2.5 mg b.i.d., 5 mg b.i.d., and 10 mg
b.i.d., respectively. Results were similar for the mean (SD)
changes from baseline to endpoint in weight: 0.48 kg (1.57),
1.72 kg (2.04), 1.62 kg (2.17), and 1.44 kg (1.91) for PBO;
asenapine, 2.5 mg b.i.d., 5 mg b.i.d., and 10 mg b.i.d.,
respectively. With the exception of weight and BMI in-
creases, mean changes in vital signs were similar across all
treatment groups. Orthostatic hypotension-related TEAEs
were reported by 7 (6.9%), 10 (9.6%), 15 (15.2%), and 8 (8.1%)
of PBO, asenapine 2.5 mg, 5 mg, and 10 mg b.i.d. groups,JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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FIGURE 2 Least-squares (LS) mean change from baseline
(with 95% CIs) by day (mixed model for repeated measures
[MMRM; full analysis set]). (A) Young Mania Rating Scale
(YMRS) total score. Unadjusted p values for treatment
comparisons with placebo (PBO): ap < .001; bp < .01; cp <
.05 (B) Clinical Global Impression Scale for use in Bipolar
Illness (CGI-BP) overall score. Unadjusted p values for
treatment comparisons with PBO: ap <.01; bp < .05.
A
B
ASENAPINE IN PEDIATRIC BP-Irespectively. Among the orthostatic hypotension-related
TEAEs (PTs: confusional state, dizziness, orthostatic hypo-
tension, postural orthostatic tachycardia syndrome, vertigo,
and presyncope), dizziness had the highest incidence,
reported in 3 (3.0%), 6 (5.8%), 10 (10.1% [p < .05]), and
5 (5.1%) patients who received PBO, asenapine 2.5 mg b.i.d.,
asenapine 5 mg b.i.d., and asenapine 10 mg b.i.d., respec-
tively. With respect to QT-related AEs, identiﬁed using the
MedDRA SMQ Torsade de Pointes/QT prolongation
(broad), there were no cases of Torsade de Pointes in the
trial. However, 2 patients experienced syncope, which is
within the broad SMQ; these patients comprised 1 individ-
ual in the asenapine 2.5 mg b.i.d. group and another in the
asenapine 5 mg b.i.d. group. Neither of these TEAEs was
serious or led to discontinuation of the study.
For lipid and endocrine parameters, the mean (SD)
changes from baseline for fasting insulin, cholesterol, tri-
glycerides, low-density lipoprotein, and glucose were larger
in asenapine groups than PBO (Table 2). Based on inferential
analysis, results were only statistically signiﬁcantly larger for
fasting glucose levels in the asenapine 2.5 mg b.i.d. group
compared with placebo. A dose–response relationship
was suggested for mean changes in fasting cholesterol
and triglyceride levels. However, differentiation was notJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
VOLUME 54 NUMBER 12 DECEMBER 2015suggested for any of the asenapine groups compared with
PBO for hemoglobin A1c, fasting insulin, and prolactin
based on inferential analysis. The frequency of patients with
shifts from baseline to endpoint in lipid and endocrine
values outside of the predeﬁned limits of change are shown
in Table S4, available online. The percentage of patients
whose insulin level (fasting and total) that met predeﬁned
limits of change 1.2 times the upper limit of normal was
higher in all the asenapine treatment groups, most notably
for asenapine 2.5 mg b.i.d. compared to placebo. Results of
the shift analysis suggest a treatment effect. A TEAE of
hyperinsulinemia (which includes the preferred terms
hyperinsulinemia and blood insulin increased) was reported
in 2% of the 302 patients treated with any dose of asenapine.
Using the C-SSRS, suicidal ideation was reported by
5 (5%), 5 (4.8%), 6 (6.1%), and 8 (8.1%) patients in the PBO,
asenapine 2.5 mg, 5 mg, and 10 mg b.i.d. groups, respec-
tively. Of these patients, 17 (71%) had a history of suicidal
behavior in the pretreatment period. Nine patients reported
TEAEs of suicidal ideation: PBO, 1 (1.0%); asenapine 2.5 mg,
4 patients (3.8%); asenapine 5 mg, 1 patient (1.0%); and 10
mg b.i.d., 3 patients (3.0%). These TEAEs were generally
transient, with no temporal pattern. One patient in the PBO
group reported an SAE of suicidal behavior and dis-
continued for this reason. One patient in the asenapine
10 mg b.i.d. group attempted suicide; however, the incident
was attributed to the recent death of a loved one. There were
no other reports of suicidal ideation that included intent or
suicidal behavior. Four patients who discontinued because
of other TEAEs (nausea, somnolence, abdominal discomfort,
and worsening of mania) reported suicidal ideation before
the discontinuation time point. All other patients completed
the trial and were enrolled in the extension phase, with
the exception of the patient who attempted suicide.
Themean change from baseline to day 21 in EPS rating scale
results was –0.1 for PBO and asenapine 2.5 mg, –0.3 for ase-
napine 5 mg, and 0.2 for asenapine 10 mg b.i.d. patients.
TEAEs within the EPS SMQ that occurred in 2% of patients
were akathisia and Parkinsonism. Akathisia was reported by
0%, 1.9%, 2.0%, and 1.0% of patients treated with placebo,
asenapine 2.5 mg, 5 mg, and 10 mg b.i.d., respectively.
Parkinsonism was reported by 0%, 1%, 0%, and 2% of patients
in placebo, asenapine 2.5 mg, 5 mg, and 10 mg b.i.d. groups,
respectively. Akathisia and dystonia were the only events
within the EPS SMQ (narrow) that led to discontinuation
(Table S3, available online), each of which resulted in 1
discontinuation (a patient in the asenapine 2.5 mg b.i.d. group
discontinued because of akathisia and a patient in the asenapine
5 mg b.i.d. group discontinued because of dystonia).
With regard to the subgroup analyses, no noticeable
difference in TEAEs was reported between patients with and
without ADHD (Table S5A, available online), between
patients with and without stimulant use (Table S5B, avail-
able online), between gender, or age of onset (data not
shown). Although there were no differences in weight, BMI,
or abdominal girth noted in the ADHD subsets, there was a
trend toward greater weight gain for asenapine compared
with PBO in the no-concomitant stimulant versus concomi-
tant stimulant use subset.www.jaacap.org 1037
FIGURE 3 Least-squares (LS) mean change from baseline
asenapine (ASN) versus placebo in Young Mania Rating Scale
(YMRS) total score on day 21, and difference of ASN versus
placebo in patient subsets. Note: ADHD ¼ attention-deficit/
hyperactivity disorder; FAS ¼ full analysis set; LS ¼ least
squares; MMRM ¼ mixed model for repeated measures. (A)
Full analysis set. ap ¼ .008 versus placebo; bp < .001 versus
placebo. (B) Patients with and without comorbid ADHD;
p ¼ .680 (not significant) for the treatment effect interaction
with ADHD. (C) Patients with and without concomitant stimulant
use; p ¼ .135 (not significant) for the treatment effect
interaction with concomitant stimulant use.
FINDLING et al.DISCUSSION
Other treatment options are needed for pediatric patients
with bipolar I disorder because patients respond differently
to medical interventions. Asenapine is another treatment
option for this patient population. This is the ﬁrst random-
ized, double-blind, PBO-controlled trial of asenapine for the
treatment of bipolar I disorder in pediatric patients with a
manic or mixed episode. Primary efﬁcacy analysis deter-
mined that all 3 doses of asenapine were superior to PBO in1038 www.jaacap.orgthe reduction of mania, as measured by change from base-
line in YMRS total score at day 21. Key secondary efﬁcacy
analysis determined that all 3 doses of asenapine were
superior to PBO in the reduction of the severity of illness as
measured by the CGI-BP overall score at day 21. Statistically
signiﬁcant improvements in both YMRS and CGI-BP scores
were observed from days 4 and 7 onward, respectively.
No signiﬁcant differences in YMRS total score between
the asenapine dose groups versus PBO were observed in
patients with and without ADHD, with and without con-
comitant stimulant use, or with respect to age and gender. It
should be noted that few other data exist to speciﬁcally
address the efﬁcacy and safety of atypical antipsychotics
in the treatment of bipolar I disorder in pediatric and
adolescent patients with ADHD and concomitant stimu-
lant use.
The TEAEs that occurred more frequently with asenapine
than PBO were somnolence, sedation, oral hypoesthesia,
oral paresthesia, and increased appetite. With the exception
of oral hypoesthesia and paraesthesia, these are common
to atypical antipsychotic agents. Of note, no patient dis-
continued treatment due to oral hypoesthesia, and 1 patient
(asenapine 2.5 mg b.i.d.) discontinued owing to paraes-
thesia. The TEAEs of oral hypoesthesia and paresthesia are
unique to asenapine and result from the local anesthetic
properties of the sublingual formulation. These effects are
reversible, generally transient, and, in this study, did not
have a signiﬁcant impact on treatment adherence. Similarly,
the incidence of clinically signiﬁcant weight gain at endpoint
was statistically signiﬁcant versus that of PBO in all 3 ase-
napine groups (asenapine range 8.0%–12.0% versus placebo
1.1%, p < .05). In general, the incidence of weight gain
among atypical antipsychotic agents appears to be higher
in adolescents than in adults. However, there are no head-
to-head data comparing other agents with asenapine in
adolescents. The mean change from baseline in fasting
insulin was larger for asenapine-treated patients than for
placebo-treated patients; however, based on inferential
analysis using 95% CIs, differentiation was not suggested for
any of the asenapine treatment groups compared with PBO.
Of asenapine-treated patients, 10.3% to 27.5% had insulin
levels shift 1.2 times the upper limit of normal. The mean
(SD) changes from baseline for cholesterol, triglycerides,
low-density lipoprotein, and glucose were also larger in
asenapine groups than in the PBO group. However, results
were only statistically signiﬁcantly larger for fasting glucose
levels in the asenapine 2.5 mg b.i.d. group versus PBO.
These results suggest the potential for substantial long-term
metabolic changes in pediatric patients treated with asena-
pine. Because of the known metabolic side effects that
occur in children and adolescents prescribed atypical anti-
psychotics, baseline and period monitoring of metabolic
parameters including BMI, lipids, and glucose levels is
recommended.
Suicidal ideation/behavior appeared to be similar across
treatment arms and did not appear to have a speciﬁc asso-
ciation with asenapine. In addition, among the TEAEs
related to orthostatic hypotension, dizziness had the highest
incidence and did not appear to be dose dependent.JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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TABLE 2 Analysis of Safety Events in Treatment Phase of All-Patients-as-Treated Population
Adverse event Placebo (n ¼ 101) n (%)
Asenapine
2.5 mg (n ¼ 104) n (%) 5 mg (n ¼ 99) n (%) 10 mg (n ¼ 99) n (%)
Patient reporting any AE
1 TEAEa 56 (55.4) 78 (75.0) 72 (72.7) 85 (85.9)
1 treatment-related TEAE 39 (38.6) 71 (68.3) 68 (68.7) 76 (76.8)
SAE 3 (3.0) 0 (0.0) 2 (2.0) 2 (2.0)
Treatment-emergent SAEa 1 (1.0) 0 (0.0) 0 (0.0) 0 (0.0)
Died 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Discontinued because of AE 4 (4.0) 7 (6.7) 5 (5.1) 5 (5.1)
Discontinued because of TEAE 2 (2.0) 7 (6.7) 3 (3.0) 5 (5.1)
Discontinued because of SAE 2 (2.0) 0 (0.0) 1 (1.0) 0 (0.0)
Discontinued due to treatment-related SAE 1 (1.0) 0 (0.0) 0 (0.0) 0 (0.0)
Key safety events
Akathisia 0 (0) 2 (1.9) 2 (2.0) 1 (1.0)
Dizziness 3 (3.0) 6 (5.8) 10 (10.1)b 5 (5.1)
Hypoesthesia oral, dysgeusia 4 (4.0) 21 (20.2)b 21 (21.2)b 25 (25.3)b
Insomnia 3 (3.0) 3 (2.9) 4 (4.0) 3 (3.0)
Extrapyramidal symptoms (narrow risk set) 2 (2.0) 4 (3.8) 4 (4.0) 5 (5.1)
Somnolence, sedation, hypersomnia combined 12 (11.9) 49 (47.1)b 52 (52.5)b 48 (48.5)b
Weight gain (7%) from baseline to endpointc 1/89 (1.1) 11/92 (12.0)b 8/90 (8.9)b 7/87 (8.0)b
Change from baseline to endpoint in lipid and
endocrine parametersd Mean (SD)
Cholesterol, fasting, mmol/L e0.060 (0.526) 0.095 (0.493) 0.186 (0.535) 0.240 (0.462)
Triglycerides, fasting, mmol/L e0.074 (0.443) 0.098 (0.544) 0.151 (0.605) 0.166 (0.526)
Glucose, fasting, mmol/L e0.12 (0.49) 0.08 (0.56) e0.02 (0.70) 0.02 (0.72)
Hemoglobin A1c, m/L e0.0005 (0.0015) e0.0002 (0.0016) e0.0002 (.0018) e0.0001 (0.0016)
Insulin, fasting, pmol/L 3.690 (93.613) 73.375 (304.655) 114.042 (265.919) 59.846 (211.300)
Prolactin, mg/L 2.525 (12.887) 3.205 (13.935) 2.093 (12.706) 6.408 (16.494)
Inferential analysis of lipid and endocrine
parameters
Difference estimate (95% CI)
2.5 mg b.i.d. vs. placebo 5 mg b.i.d. vs. placebo 10 mg b.i.d. vs. placebo
Cholesterol, fasting, mmol/L 0.156 (0.037, 0.350) 0.231 (0.042, 0.420) 0.299 (0.105, 0.492)
Triglycerides, fasting, mmol/L 0.176 (0.032, 0.384) 0.197 (0.006, 0.400) 0.229 (0.020, 0.437)
Glucose, fasting, mmol/L 0.21 (0.02, 0.41) 0.12 (0.07, 0.32) 0.18 (0.02, 0.37)
Hemoglobin A1c, m/L 0.0003 (0.0002, 0.0009) 0.0004 (0.0001, 0.0009) 0.0005 (0.0000, 0.0010)
Insulin, fasting, pmol/L 54.172 (48.359, 156.702) 91.388 (7.931, 190.707) 57.386 (49.520, 164.293)
Prolactin, mg/L 0.851 (5.077, 3.376) 0.747 (4.943, 3.449) 1.885 (2.422, 6.192)
Note: AE ¼ adverse event; SAE ¼ serious adverse event; TEAE ¼ treatment-emergent adverse event.
aAn adverse event is a treatment-emergent adverse event if it is newly reported after baseline or reported to have worsened in severity since baseline.
bp < .05. For adverse events, every patient is counted a single time for each applicable row. Weight was based on patients with a baseline and at least 1 postbaseline value; all other p  .05.
cDerived from the continuous variable weight (kg).
dFor each laboratory test, only patients with baseline and at least 1 value during treatment phase were included.
JO
U
RN
A
L
O
F
TH
E
A
M
ERIC
A
N
A
C
A
D
EM
Y
O
F
C
H
ILD
&
A
D
O
LESC
EN
T
P
SYC
H
IA
TRY
VO
LU
M
E
54
N
U
M
BER
12
D
EC
EM
BER
2015
w
w
w
.jaacap.org
1
0
3
9
A
SEN
A
PIN
E
IN
PED
IA
TRIC
BP-I
FINDLING et al.Although there were no signiﬁcant differences among the 3
asenapine groups and placebo with respect to TEAEs clas-
siﬁed as SMQ EPS (narrow), there were higher incidences of
SMQ Parkinson-like events (narrow) for the asenapine 10 mg
b.i.d. group, suggesting differentiation.
One study limitation is that these results may not be
generalizable to the entire child and adolescent population
with bipolar I disorder because of the inclusion and exclu-
sion criteria used in this study and the relative heterogeneity
of this patient population. Also, the short-term nature of the
trial does not permit long-term efﬁcacy and safety conclu-
sions to be drawn. A 50-week extension of this core trial has
been completed, and those data are anticipated to be pub-
lished in 2016. In addition, a list of each medication that all
patients discontinued before entering the study is unknown.
Furthermore, the CGI-Improvement scale was not used.
Finally, it is worth noting that accurate diagnosis of bipolar I
disorder in pediatric patients may be challenging. The
diagnostic criteria set forth by the DSM-5 has added
increased energy into the “A criterion” for the diagnosis of a
manic episode. It is unclear how this might affect the results
of clinical trials that previously enrolled patients on the basis
of the DSM-IV criteria. &10Accepted September 25, 2015.
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